



CURRICULUM VITAE

Haritha Pabbathi, MD

CURRENT AFFILIATION:

Employer: Northwest Georgia Oncology Centers, P.C.
Position: Physician (PRN)
Primary Office: 111 Medical Drive
LaGrange, GA 30240
Phone: (706) 812-2426
Fax: (706) 812-2427

EDUCATION:

MEDICAL EDUCATION:
MBBS, 06/1994 – 06/1999
Gandhi Medical College
Secunderabad, India

POSTDOCTORAL TRAINING:

Internship
Gandhi Hospital
Secunderabad, India
06/1999 to 07/2000

Internship (Internal Medicine)
Englewood Hospital and Medical Center, Mt. Sinai School of Medicine
Englewood, NJ
07/2003 to 06/2004

Residency (Internal Medicine)

Englewood Hospital and Medical Center, Mt. Sinai School of Medicine
Englewood, NJ
07/2004 to 06/2006

Fellowship (Hematology and Medical Oncology)

Long Island Jewish Health System, Lenox Hill Hospital
New York, NY
07/2007 to 06/2010

LICENSURE AND CERTIFICATION:

State of Georgia, Physician License #64236
National Provider Number (NPI): 1215000989
American Board of Internal Medicine, Medical Oncology, 2019
American Board of Internal Medicine, Hematology, 2010

WORK HISTORY:

**Physician, Medical Oncology & Hematology
(PRN)**

Northwest Georgia Oncology Centers, PC
LaGrange, GA
Expected Start Date: 11/05/2024

Physician, Breast Medical Oncology

Northside Hospital, Georgia Cancer Specialists
Macon, GA
02/2023-Present

Tele-Physician, Oncology & Hematology

Eagle Telemedicine
Remote
08/2022-Present

Physician, Oncology

Cancer Treatment Centers of America,
Southeastern Regional Medical Center
Newnan, GA
11/2012-07/2022

Attending Physician

Emory Specialty Associates, Clark-Holder Clinic
LaGrange, GA
09/2010-10/2012

Consulting Physician

West Georgia Medical System
LaGrange, GA
09/2010-10/2012

Hospitalist

Oconee Memorial Hospital
Seneca, SC
10/2006-01/2007

PROFESSIONAL SOCIETIES:

American Medical Association, Member
American Society for Clinical Oncology, Member
American Society for Hematology, Member

RESEARCH:

Principal Investigator:

Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

- a. Protocol Number: ODO-TE-B301
- b. Sponsor: Odonate Therapeutics, Inc.

Sub-Investigator:

1. Title: The Xenera™-1 study tests xentuzumab in combination with everolimus and exemestane in post-menopausal women with hormone receptor positive and HER2-negative breast cancer that has spread

- a. Protocol Number: 1280-0022
- b. Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.

2. Title: Phase 1/2, Multicenter, Open-Label, Multiple Dose First-In-Human Study of U3-1402, in Subjects with HER3 Positive Metastatic Breast Cancer

- a. Protocol Number: U31402-A-J101
- b. Sponsor: Daiichi Sankyo

3. Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
 - a. Protocol Number: ONT-380-206
 - b. Sponsor: Seattle Genetics, Inc.

4. Title: A randomized phase II study of neoadjuvant carboplatin/paclitaxel (CT) versus panitumumab/carboplatin/paclitaxel (PaCT) followed by anthracycline-containing regimen for newly diagnosed primary triple-negative inflammatory breast cancer
 - a. Protocol Number: 2016-0177
 - b. Sponsor: MD Anderson Cancer Center

5. Title: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)
 - a. Protocol Number: MK-3475-756
 - b. Sponsor: Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc.)

6. Title: A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant Trial with Ribociclib [LEE011]: NATALEE)
 - a. Protocol Number: CLEE011O12301C (TRIO033)
 - b. Sponsor: Novartis Pharmaceuticals Corporation

7. Title: A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients with Early Triple-Negative Breast Cancer
 - a. Protocol Number: C3441020
 - b. Sponsor: Pfizer

8. Title: My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
 - a. Protocol Number: ML28897/PRO 02
 - b. Sponsor: Genentech, Inc.

9. Title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
 - a. Protocol Number: CP-MGAH22-04

b. Sponsor: MacroGenics, Inc.

10. Title: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

a. Protocol Number: IRB00091808

b. Sponsor: American Society of Clinical Oncology (ASCO)

Haritha Pabbathi, MD
September 10, 2024

